CD30 Expression in Germinal Center B-cell-like and non-Germinal Center B-cell-like Subtypes of Diffuse Large B-cell Lymphoma
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common and most heterogeneous type of non-Hodgkin lymphoma. With current therapeutic modalities, 30%–40% of DLBCL cases still experience recurrence. The discovery of CD30 expression in DLBCL in several studies has opened up alternative opportunities for new target therapies.
AIM: This cross-sectional study aimed to determine CD30 expression in DLBCL and its difference in expression in germinal center B-cell such as (GCB) and non-GCB subtypes.
METHODS: The sample consisted of 25 GCB and 25 non-GCB cases based on immunohistochemical examination performed at Cipto Mangunkusumo Hospital from 2014 to 2017. CD30 staining was carried out and assessed using tumor cells percentage with positive cutoff values of >0%, >10%, and >20%.
RESULTS: Positive CD30 expression was obtained in 8 (16%), 4 (8%), and 3 (6%), out of 50 DLBCL cases with positive cutoff values of >0%, >10%, and >20%, respectively. We performed Fisher’s exact test to determine CD30 expression in the GCB and non-GCB subtypes and found no significant difference with p > 0.05.
CONCLUSION: Our study found no significant difference between CD30 expression in the GCB and non-GCB subtypes of DLBCL.
Plum Analytics Artifact Widget Block
Rinaldi I, Hardjolukito ES, Prajogi GB, Giselvania A, Nuhonni SA. Panduan Penatalaksanaan Limfoma non Hodgkin. Jakarta: Komite Nasional Penanggulangan Kanker; 2015. p. 1-8.
Chiu BC, Hou N. Epidemiology and etiology of non- Hodgkin lymphoma. In: Evens AM, Blum KA, editors. Non- Hodgkin Lymphoma Pathology, Imaging, and Current Therapy. Switzerland: Springer; 2015. p. 1-25. https://doi. org/10.1007/978-3-319-13150-4_1
Gascoyne RD, Campo E, Jaffe ES, Staudt LM. Diffuse large B-cell lymphoma, NOS. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA., editors. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. 4th ed. London: IARC; 2017. p. 291-7.
Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller- Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: Review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016;101(10):1244-50. https://doi.org/10.3324/ haematol.2016.148809 PMid:27354024
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82. https:// doi.org/10.1182/blood-2003-05-1545 PMid:14504078
Rovira J, Valera A, Colomo L, Setoain X, Rodríguez S, Martínez- Trillos A, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015;94(5):803-12. https://doi.org/10.1007/s00277-014-2271-1 PMid:25501975
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715-24. https://doi.org/10.341 0/f.717989810.793472956 PMid:23343832
Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin- Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-31. https://doi.org/10.1182/ blood-2010-09-297879 PMid:21119107
de Leval L, Gaulard P. CD30+ lymphoproliferative disorders. Haematologica. 2010;95(10):1627-30. https://doi.org/10.3324/ haematol.2010.029256 PMid:20884717
Salas Q, Climent F, Tapia G, Riasol M, Mercadal S, Domingo E. CD30 expression in diffuse large B-cell lymphoma correlates with non-GCB subtype but does not have prognostic impact in patients treated with first line R-CHOP/R-CHOP-like. Hematol Oncol. 2017;35:290-1. https://doi.org/10.1002/hon.2439_19
Gong QX, Wang Z, Liu C, Li X, Lu TX, Liang JH, et al. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. J Clin Pathol. 2018;71(9):795- 801. https://doi.org/10.1136/jclinpath-2018-205039 PMid:29666157
Hao X, Wei X, Huang F, Wei Y, Zeng H, Xu L, et al. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. PLoS One. 2015;10(5):e0126615. https://doi.org/10.1371/ journal.pone.0126615 PMid:25974110
Xu J, Oki Y, Saksena A, Desai P, Lin P, Tang G, et al. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Hum Pathol. 2017;60:160-6. https://doi.org/10.1016/j.humpath.2016.10.009 PMid:27816715
van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603. https://doi.org/10.1038/bcj.2017.85 PMid:28885612
Gouveia GR, Siqueira SA, Pereira J. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter. 2012;34(6):447-51. https://doi. org/10.5581/1516-8484.20120111 PMid:23323070
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146-71. https://doi. org/10.1016/j.critrevonc.2012.12.009 PMid:23375551
Chen P, Jiang MQ, Ruan XZ, Cai NL, Ye XW, Pan YN, et al. The phenotypes of germinal center B-cell-like (GCB) and non-GCB failed to predict the survival of patients with diffuse large B-cell lymphoma in the rituximab era. Int J Clin Exp Med. 2017;10:13564-70.
Wang XJ, Seegmiller AC, Reddy NM, Li S. CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. Eur J Haematol. 2016;97(1):39-47. https://doi.org/10.1111/ejh.12680 PMid:26340843
Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, Chapman- Fredricks JR. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: A retrospective study of 167 cases. Leuk Lymphoma. 2013;54(11):2405-11. https://doi.org/10.3109/1042 8194.2013.778407 PMid:23432725
Bartlett NL, Sharman JP, Oki Y, Advani RH, Bello CM, Winter JN, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim result in patient with DLBCL and other B-Cell lymphoma. Blood. 2013;122:848. https://doi.org/10.1182/ blood.v122.21.848.848
Copyright (c) 2020 Patricia Fransisca Julianty, Maria Francisca Ham, Kusmardi Kusmardi, Agnes Stephanie Harahap (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.